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Background: Anti-CADM-140 antibody (anti-CADM-140), also referred to as anti-melanoma
differentiation-associated gene 5 (MDA5) antibody, is a myositis-specific antibody identified
in the sera of patients with clinically amyopathic dermatomyositis (C-ADM) and is associated
with a worse prognosis in dermatomyositis-associated interstitial lung disease (DM-ILD). We
sought to determine high-resolution computed tomography (HRCT) features of DM-ILD with
anti-CADM-140.
Methods: Twenty-five patients newly diagnosed with DM-ILD at Kyoto University Hospital
between 2005 and 2009 were retrospectively reviewed. Serum anti-CADM-140 was measured
in all patients at their first visit. Chest HRCT images taken prior to treatment were classified
based on the dominant findings and their distribution, and compared between patients with
and without the antibody.
Results: Of 25 DM-ILD patients, 12 were positive and 13 were negative for anti-CADM-140.of Rehabilitation Medicine, Kyoto University Hospital, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto 606-
ax: þ81 75 751 4643.
-u.ac.jp (T. Handa).
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HRCT in DM-ILD with anti-CADM-140 1381HRCT patterns differed significantly between anti-CADM-140-positive and negative patients
(P Z 0.002). Lower consolidation or ground-glass attenuation (GGA) pattern (50.0%) and
random GGA pattern (33.3%) were the predominant patterns in anti-CADM-140-positive cases,
while lower reticulation pattern (69.2%) was frequently seen in anti-CADM-140-negative cases.
Anti-CADM-140-positive cases were also significantly characterized by the absence of intralob-
ular reticular opacities (0% in anti-CADM-140 (þ) vs. 84.6% in anti-CADM-140 (), P < 0.0001).
Conclusions: Anti-CADM-140-positive DM-ILD was characterized by lower consolidation or GGA
pattern, random GGA pattern, and the absence of intralobular reticular opacities.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung disease (ILD) is observed in 5e65% of pol-
ymyositis (PM) and dermatomyositis (DM) cases,1,2 and is
a significant prognostic factor.1 PM/DM-associated ILD (PM/
DM-ILD) can be divided into acute and chronic types.3 The
acute type of PM/DM-ILD is often rapidly progressive and
refractory to treatment, resulting in fatal outcome.3
PM and DM are also characterized by several serum
autoantibodies specific to PM/DM, designated as myositis-
specific antibodies (MSAs).4 Anti-CADM-140 antibody (anti-
CADM-140) was the MSA identified in 2005 by Sato and
coworkers in the sera of patients with clinically amyopathic
dermatomyositis (C-ADM).5 It recognizes interferon (IFN)-
induced with helicase C domain protein 1/melanoma
differentiation-associated gene 5 (IFIH1/MDA5)6 and is thus
also referred to as anti-MDA5 antibody.7 It is specific to DM
and is associated with the acute type of DM-ILD.6,7 As
expected from these findings, anti-CADM-140 was reported
to be associated with a worse prognosis in patients with DM-
ILD, compared to anti-aminoacyl-tRNA synthetase (ARS)
antibodies (anti-ARS).7 On the other hand, acute and
chronic types of DM-ILD were shown to display different
radiological features.3 However, the radiological features
of DM-ILD with anti-CADM-140 or the relationships between
anti-CADM-140 and radiological findings have not been
elucidated thus far.
In the present study, we aimed to define high-resolution
computed tomography (HRCT) features of DM-ILD with
anti-CADM-140. We compared HRCT findings between anti-
CADM-140-positive and negative DM-ILD cases, and investi-
gated whether the HRCT features could discriminate
between the antibody-positive and negative cases.
Methods
Patients
The study population included all patients who were diag-
nosed with DM at Kyoto University Hospital between 2005
and 2009. DM was diagnosed using the Bohan and Peter
criteria.8 C-ADM was diagnosed if a patient had the char-
acteristic skin rash of DM but little or no muscle symptoms
and serum creatine kinase (CK) was <300 IU/L during the
study period, as described previously.5,6 We excluded
patients who had active neoplasm or other connective
tissue disease (CTD), or had been treated with systemic
corticosteroid (CS) or immunosuppressive agents beforereferral to our hospital. Among the remaining 32 patients,
ILD was confirmed in 25 (78.1%) based on HRCT. Acute and
subacute DM-ILD subtypes were diagnosed when respiratory
failure developed within 1 month and within 1e3 months,
respectively, from the onset of symptoms or the initiation
of treatment.
All patients provided written informed consent before
blood sample collection. The Kyoto University Hospital
Institutional Review Board approved this retrospective
study.
Clinical evaluation
Clinical information was retrospectively collected from
medical records. All patients were evaluated by at least
two rheumatologists prior to treatment and had blood tests
at their first visit. Most patients also underwent standard-
ized pulmonary function tests,9 and arterial blood gas
analysis was done before treatment. Published equations
for Japanese adults were used to determine predicted
values of each parameter.10
Measurement of MSAs
Serum samples were obtained from all patients at the first
visit prior to receiving immunosuppressive therapies. The
presence of MSAs was determined by RNA-immunoprecipi-
tation (RNA-IPP) for anti-ARS and protein-immunoprecipi-
tation (P-IPP) for anti-CADM-140 as described previously.6
Patients were divided into two groups based on the pres-
ence or absence of anti-CADM-140: anti-CADM-140 (þ) or
(), respectively.
HRCT scanning protocol
Thin-section CT images were obtained with a multi-
detector CT scanner (Aquilion 64; Toshiba Medical Systems,
Tochigi, Japan). Whole lung scans were performed at peak
tube voltage of 120 kVp with variable mAs setting using an
automatic exposure control system (SD value 8.5). Contig-
uous 7-mm-thick images and HRCT images (2 mm) were
prepared for review.
HRCT evaluation
All patients underwent chest HRCT prior to treatment, and
images were reviewed by three independent observers
(T.K., T.H., and K.T. with 15, 12, and 10 years of
1382 K. Tanizawa et al.experience, respectively) blinded to clinical information.
Inter-observer disagreements were resolved by consensus.
Images were assessed for the presence of ground-glass
attenuation (GGA), consolidation, intralobular reticular
opacities, interlobular septal thickening, non-septal linear
or plate-like opacity, substantial micronodules, honey-
combing, emphysema, traction bronchiectasis, and lobar
volume loss. The presence of mediastinal lymph node
enlargement or pleural effusion and the laterality of
abnormalities were also assessed. HRCT findings were
interpreted according to the recommendations of the
Nomenclature Committee of the Fleischner Society.11 Non-
septal linear or plate-like opacity was defined as an elon-
gated line of soft tissue attenuation that was distinct from
interlobular septa and bronchovascular bundles, including
subpleural curvilinear lines and subpleural bands.12
Through reviewing all HRCT images, we found that all 25
cases could be categorized into a few HRCT patterns, based
on dominant CT findings, and the craniocaudal and axial
distribution of these findings. The dominant findings were
classified as GGA, consolidation, or reticulation (intra-
lobular reticular opacities, interlobular septal thickening,
or non-septal linear or plate-like opacity). The craniocaudal
distribution was assessed as upper, lower, diffuse, or
random. Upper distribution was defined as extensive find-
ings predominantly above the level of inferior pulmonary
veins, lower when there were more below this level, diffuse
when generalized, and random for no zonal predominance.Table 1 Patient demographic, clinical characteristics and labo




Age (years) 53.5  9.4
C-ADM at diagnosis 6 (50.0%)
Acute ILDa 3 (25.0%)
Acute or subacute ILDb 5 (41.7%)
Laboratory tests
WBC (/mm3) 5140  1390 (n Z 12)
Plt (104/mm3) 19.8  7.09 (n Z 12)
CRP (mg/dL) 1.03  0.84 (n Z 12)
LDH (IU/L) 423.2  199.4 (n Z 12)
CK (IU/L) 261.3  314.6 (n Z 12)
Aldolase (IU/L) 9.0  4.4 (n Z 12)
Ferritin (ng/mL) 1267.6  2077.3 (n Z 10)
Maximal ferritinc (ng/mL) 3035.7  5253.2 (n Z 10)
KL-6 (U/mL) 511.8  162.3 (n Z 12)
SP-D (ng/mL) 44.0  20.0 (n Z 8)
Anti-ARS antibodies 0 (0.0%)
All values are number (percentage) or mean  standard deviation (n
Abbreviations: anti-CADM-140, anti-CADM-140 antibody; C-ADM, clini
WBC, white blood cell; Plt, platelet; CRP, C-reactive protein; LDH, lact
D; ARS, aminoacyl-tRNA synthetase.
a Acute ILD was diagnosed when respiratory failure developed with
treatment.
b Subacute ILD was diagnosed when respiratory failure developed w
initiation of treatment.
c Highest value through the whole course.The axial distribution was classified as peribronchovascular
when the dominant findings were along the bronchi and
vessels, peripheral when in the outer one-third of the lung,
diffuse when generalized, or random when no distribution
pattern was apparent.
Statistical analysis
Statistical analysis was performed using JMP version 6 (SAS
Institute Inc. Cary, NC, USA). All statistical variations in
quantitative data were expressed as a single determination
standard deviation, and a P value less than 0.05 was
considered to indicate statistical significance.
Group comparisons were made using Fisher’s exact test,
c2 test, and ManneWhitney U test. Cumulative survival
probabilities were estimated using the KaplaneMeier
method and the log-rank test.
Results
Initial clinical features
Demographics, clinical manifestations and laboratory test
results of patients in the anti-CADM-140 (þ) and () groups
are summarized in Table 1. The prevalence of C-ADM
showed no significant difference (50.0% vs. 30.8%,
PZ 0.43). Acute DM-ILD was diagnosed in 25% of patients inratory test results at diagnosis.
) Anti-CADM-140 () (n Z 13) P
4/9 >0.99
6 (46.2%) 0.01




8860  2940 (n Z 13) <0.01
29.9  9.38 (n Z 13) <0.01
1.52  1.76 (n Z 13) 0.81
429.2  161.7 (n Z 13) 0.96
1348.8  1707.0 (n Z 13) <0.01
25.1  26.5 (n Z 13) 0.03
196.7  252.0 (n Z 10) 0.01
1575.2  4117.5 (n Z 10) 0.04
907.2  750.4 (n Z 12) 0.32
154.1  119.4 (n Z 8) <0.01
10 (76.9%) <0.01
umber).
cally amyopathic dermatomyositis; ILD, interstitial lung disease,
ate dehydrogenase; CK, creatine kinase; SP-D, surfactant protein-
in one month from the onset of symptoms or the initiation of
ithin one to three months from the onset of symptoms or the
Table 2 HRCT findings in anti-CADM-140 (þ) and () groups.
Anti-CADM-140 (þ) (n Z 12) Anti-CADM-140 () (n Z 13) P
Ground-glass attenuation 10 (83.3%) 13 (100.0%) 0.22
Consolidation 7 (58.3%) 6 (46.2%) 0.70
Intralobular reticular opacities 0 (0.0%) 11 (84.6%) <0.01
Interlobular septal thickening 8 (66.7%) 6 (46.2%) 0.43
Non-septal linear or plate-like opacities 10 (83.3%) 7 (53.8%) 0.20
Honeycombing 0 (0.0%) 0 (0.0%) N.A.
Traction bronchiectasis 0 (0.0%) 3 (23.1%) 0.22
Lobular volume loss 5 (41.7%) 7 (53.8%) 0.70
HRCT pattern
Lower consolidation/GGA 6 (50.0%) 2 (15.4%)
Lower reticulation 0 (0.0%) 9 (69.2%) <0.01
Random GGA 4 (33.3%) 0 (0.0%)
Othersa 2 (16.7%) 2 (15.4%)
All values are number (percentage).
Abbreviations: N.A., not available; GGA, ground-glass attenuation.
a In the anti-CADM-140 (þ) group, upper GGA pattern in one and diffuse GGA in another. In the anti-CADM-140 () group, lower but
axially diffuse GGA pattern in one and diffuse reticulation in another.
Fig. 1 High-resolution computed tomography (HRCT) images
showing lower consolidation/ground-glass attenuation (GGA)
pattern in a 44-year-old man positive for anti-CADM-140 anti-
body (anti-CADM-140). A and B: At diagnosis, peripheral and
peribronchovascular consolidations were observed (arrow-
heads). Interlobular septal thickening and non-septal linear or
plate-like opacities were also seen (arrows). C and D: Despite
treatment for 6 weeks, severe respiratory failure developed,
requiring mechanical ventilation. Diffuse GGA and consolida-
tion with air bronchograms were extended in the whole lungs.
Surveillance at this point revealed no evidence of infection.
The patient died of respiratory failure 1 week later.
HRCT in DM-ILD with anti-CADM-140 1383the anti-CADM-140 (þ), and 0% of patients in the anti-
CADM-140 () group (PZ 0.10), while the sum of acute and
subacute subtypes was 41.7% and 7.7%, respectively
(PZ 0.07). Before treatment, white blood cells, platelets,
CK, and aldolase levels were lower in the anti-CADM-140
(þ) group. Pretreatment ferritin and its maximal value
were both higher in the anti-CADM-140 (þ) group. In the
anti-CADM-140 () group, 10 patients (76.9%) were positive
for anti-ARS: three with EJ, three with PL-7, two with Jo-1,
one with OJ, and one with PL-12. Arterial blood gas anal-
yses and pulmonary functional tests revealed no significant
differences (data not shown). No patients underwent
surgical lung biopsy (SLB) in either group.
HRCT evaluation
HRCT findings are shown in Table 2. Common findings were
GGA (83.3%), non-septal linear or plate-like opacity
(83.3%), and interlobular septal thickening (66.7%) in the
anti-CADM-140 (þ) group; and GGA (100.0%), intralobular
reticular opacities (84.6%), non-septal linear or plate-like
opacity (53.8%), and lobular volume loss (53.8%) in the anti-
CADM-140 () group. Among the HRCT findings, intralobular
reticular opacities were significantly different between the
groups (0% in anti-CADM-140 (þ) vs. 84.6% in anti-CADM-140
(), P < 0.0001).
Next,we categorized all 25 cases into four HRCT patterns:
lower consolidation/GGA pattern (lower peripheral or peri-
bronchovascular consolidations or GGA); lower reticulation
pattern (lower peripheral or peribronchovascular reticula-
tion); random GGA pattern (random peripheral GGA); and
others. Lower consolidation/GGA pattern was characterized
by nonsegmental consolidations or GGA, with subpleural or
peribronchovascular distribution (Figs. 1 and 2). Lower
reticulation pattern showed a homogeneous distribution
with some subpleural sparing (Fig. 3). In random GGA
pattern, small GGAs were seen in a patchy manner in the
absence of consolidation (Fig. 4).
The HRCT patterns were significantly different between
the anti-CADM-140 (þ) and () groups (P Z 0.002): with
Fig. 2 A and B: HRCT images showing lower consolidation/
GGA pattern in a 51-year-old man positive for anti-CADM-140.
A: At diagnosis, subpleural nonsegmental GGA was observed. B:
Peripheral and peribronchovascular consolidations (arrow-
heads), and interlobular septal thickening and non-septal
linear or plate-like opacities (arrow) were also seen. C and D:
HRCT images showing lower consolidation/GGA pattern in a 60-
year-old man positive for anti-CADM-140. Subpleural non-
segmental consolidations with air bronchograms were observed
(arrowheads). Subpleural nonsegmental GGA was also seen
(arrow).
Fig. 3 HRCT images showing lower reticulation pattern. A: A
47-year-old woman negative for anti-CADM-140 (PL-7-positive).
Peripheral intralobular reticular opacities with subpleural
sparing were the dominant finding (arrowheads). GGAs, inter-
lobular septal thickening, non-septal linear or plate-like
opacities, and traction bronchiectasis (arrows) were also
observed. The patient remained alive 6 years after diagnosis.
B: A 52-year-old woman negative for anti-CADM-140 (Jo-1-
positive). Peripheral intralobular reticular opacities with sub-
pleural sparing were the dominant findings (arrowheads).
Interlobular septal thickening and non-septal linear or plate-
like opacities were also prominent (arrows). The patient
remained alive 6 years after diagnosis.
1384 K. Tanizawa et al.lower consolidation/GGA pattern (50.0%) and random GGA
pattern (33.3%) in the anti-CADM-140 (þ) group, and lower
reticulation pattern (69.2%) in the anti-CADM-140 () group.
Additionally, the dominant abnormalities were seen in lower
lung fields (6/12, 50%) or randomly (4/12, 33.3%) in anti-
CADM-140-positive patients, compared to lower lung fields
(12/13, 93.2%) in most anti-CADM-140-negative patients
(PZ 0.04). The HRCT patterns in the seven fatal anti-CADM-
140 (þ) cases were lower consolidation/GGA pattern in four,
random GGA pattern in two (including the one patient who
died of Pneumocystis jiroveci pneumonia and sepsis), and
others in one (Table 3). Of 10 patients with anti-ARS anti-
bodies in the anti-CADM-140 () group, six (60.0%) had
a lower reticulation pattern and two (20.0%) had lower
consolidation/GGA pattern. Three patients who were nega-
tive for both anti-CADM-140 and anti-ARS showed lower
reticulation pattern.Treatment and outcome
All patients received corticosteroid (CS) therapy, and
immunosuppressive (IS) agents; most commonly cyclo-
sporine A (CsA), used in 83.3% and 69.2% in the anti-CADM-
140 (þ) and () groups, respectively.
The median follow-up period from the diagnosis of DM
for all patients was 588 days (range, 41e1617 days). Of 12
patients in the anti-CADM-140 (þ) group, seven died and
five survived, while all 13 patients in the anti-CADM-140 ()
group survived (P < 0.01). Of the seven deaths in anti-
CADM-140 (þ) group, five patients died of progressive ILD
that was refractory to initial treatment. The remaining two
patients died after the disease had been well controlled for
months. One patient died of P. jiroveci pneumonia and
sepsis, and another of acute exacerbation of ILD without
infection. All seven patients were treated with corticoste-
roids and CsA, whereas cyclophosphamide (CYC) was used
in six patients.
Discussion
We demonstrated that radiological features of anti-CADM-
140-positive DM-ILD were significantly different from those
of anti-CADM-140-negative cases, based on the original
classification of HRCT patterns. In our series, anti-CADM-
140-positive DM-ILD was characterized by lower consolida-
tion/GGA and random GGA pattern and the absence of
intralobular reticular opacities. To our knowledge, this is
the first report describing HRCT features of DM-ILD with
anti-CADM-140 in comparison with DM-ILD without this
antibody.
Fig. 4 HRCT image showing random GGA pattern in a 56-year-old woman positive for anti-CADM-140. Small, peripheral, localized
GGAs were distributed in a patchy manner, with no consolidation. The patient remained alive 4 years after diagnosis.
HRCT in DM-ILD with anti-CADM-140 1385The HRCT patterns characterized by the dominant find-
ings and the distributions of such abnormalities were
significantly different between the anti-CADM-140 (þ) and
() groups. Lower consolidation/GGA and random GGA
patterns predominated in the anti-CADM-140 (þ) group,
while lower reticulation was more common in the anti-
CADM-140 () group. Lower reticulation pattern is consis-
tent with idiopathic nonspecific interstitial pneumonia
(NSIP)13e15 and DM/PM-ILD having biopsy-proven NSIP
pattern16: reticulation, GGAs, lobar volume loss, and lower
predominance, but little or no honeycombing. More than
half of the anti-CADM-140-negative patients (69.2%,
including six anti-ARS-positive patients) in our series had
this pattern, suggestive of pathological NSIP pattern. On
the other hand, lower consolidation/GGA and random GGA
patterns are more difficult to interpret. Lower consolida-
tion/GGA pattern may indicate organized pneumonia
(OP)14,17 or localized diffuse alveolar damage (DAD).14,17e19
The mortality in patients with this pattern was as high as
50.0% (4/8), suggesting a high prevalence of DAD although
radiopathological correlation was not confirmed in our
cases. Indeed, Kang et al. reported biopsy-proven DAD,
usual interstitial pneumonia (UIP), and NSIP patterns in DM-
ILD, while HRCT findings showed OP pattern in mostTable 3 Clinical characteristics of 12 anti-CADM-140-positive c
Case No. Age Sex C-ADM Acute/subacute ILD HRCT pattern
1 60 M e þ Lower consolid
2 51 M þ þ Lower consolid
3 44 M e þ Lower consolid
4 45 F þ þ Lower consolid
5 41 F þ e Lower consolid
6 52 F þ e Lower consolid
7 64 F þ þ Random GGA
8 64 F e e Random GGA
9 52 M e e Random GGA
10 56 F e e Random GGA
11 70 F þ e Other
12 43 F e e Other
Abbreviations: C-ADM, clinically amyopathic dermatomyositis; ILD, i
attenuation; PCP, Pneumocystis jiroveci pneumonia.
a The follow-up period from the diagnosis.cases.20 In random GGA pattern, most lesions were too
small to speculate pathology.
Another significant characteristic of anti-CADM-140-
positive DM-ILD was the absence of intralobular reticular
opacities. Intralobular reticular opacities represent
abnormal thickening of intralobular interstitial tissue11 and
were observed in 87% of idiopathic NSIP patients13 and 92%
of DM/PM-ILD patients with biopsy-proven NSIP pattern.16
Thus, the absence of lower reticulation pattern and intra-
lobular reticular opacities in the anti-CADM-140 (þ) group
indicates a lower prevalence of pathological NSIP pattern
among anti-CADM-140-positive cases, in contrast to anti-
CADM-140-negative cases. Additionally, the reported
responses to treatment and outcomes of DM/PM-ILD
patients with biopsy-proven NSIP pattern were much better
than those of our anti-CADM-140-positive patients.16
Although the prognostic value of pathology in DM-ILD have
not been established, these differences in both radiological
findings and survival suggest that the anti-CADM-140 (þ)
group includes patients distinct from those with patholog-
ical NSIP.
On the other hand, HRCT findings other than intralobular
reticular opacities were not significantly different between
the anti-CADM-140 (þ) and () groups. Our results indicateases.
Durationa (days) Outcome Cause of death
ation/GGA 64 Death Respiratory failure
ation/GGA 87 Death Respiratory failure
ation/GGA 41 Death Respiratory failure
ation/GGA 52 Death Respiratory failure
ation/GGA 97 Survival
ation/GGA 630 Survival
133 Death Acute exacerbation
92 Death PCP, sepsis
952 Survival
1237 Survival
122 Death Respiratory failure
503 Survival
nterstitial lung disease; M, male; F, female; GGA, ground-glass
1386 K. Tanizawa et al.that HRCT patterns may be more helpful in discriminating
between anti-CADM-140-positive and negative cases than
several nonspecific findings. The HRCT patterns in our study
were based on the major abnormalities and the distribu-
tions of those abnormalities to describe the overall picture
comprehensively and concisely. Thus, the complete picture
of HRCT images, rather than the presence of individual
abnormalities probably characterized anti-CADM-140-posi-
tive cases better.
Among MSAs, anti-ARS has also been reported to be
associated with ILD in DM/PM patients.21 Of 13 anti-CADM-
140-negative cases in our study, 10 were positive for anti-
ARS, and the HRCT patterns were similar between anti-ARS-
positive and negative cases: lower reticulation pattern was
predominant (60.0% and 40.0% in anti-ARS-positive and
negative patients, respectively). These findings indicate
that anti-CADM-140 may be more influential on the HRCT
patterns of DM-ILD than anti-ARS.
Notably, the prevalence of C-ADM was not significantly
different between anti-CADM-140 (þ) and () groups. In
spite of the designation, half the patients in the anti-CADM-
140 (þ) group did not fulfill the criteria for C-ADM. Such
a discrepancy between anti-CADM-140 and C-ADM was also
suggested by Gono and coworkers.7 In addition, the results
of pulmonary function tests and arterial gas analyses at
diagnosis were not significantly different. These findings
indicate that, while this antibody is a strong predictor of
mortality, the initial clinical data cannot necessarily
discriminate between anti-CADM-140-positive and negative
cases in DM-ILD. In contrast, the HRCT features were
significantly different between the two groups, suggesting
the clinical utility of HRCT evaluation for predicting the
presence of anti-CADM-140.
High mortality in the anti-CADM-140 (þ) group suggested
the necessity of novel therapies beyond the combination of
corticosteroids and immunosuppressive agents, mainly CsA
and/or CYC. On the other hand, approximately half of
patients with anti-CADM-140 (41.7%) survived with current
regimens. Table 3 suggests that the HRCT patterns may not
be associated with survival in anti-CADM-140-positive DM-
ILD; thus, the prognostic value of HRCT features at diag-
nosis is the next critical question. A recent study reported
the prognostic value of serum ferritin in DM-ILD with anti-
CADM-140, although the study population was relatively
small.7 Thus, the predictors of mortality in anti-CADM-140-
positive DM-ILD, including HRCT features should be eluci-
dated by analyzing larger numbers of patients. In addition,
in the entire spectrum of DM-ILD, the prognostic values of
HRCT features should also be compared to that of anti-
CADM-140 and other serum biomarkers. As Goh et al.
showed in systemic sclerosis-associated ILD,22 quantitative
scoring of disease extent may be helpful in these analyses.
We should mention some limitations of this study. First,
this study was a small-sized study in a single center.
Second, serial changes in HRCT images were not addressed
because follow-up HRCT was performed at rather arbitrary
intervals. The effects of treatment on HRCT features and
their prognostic values should be further studied in
a prospective design. Third, radiopathological correlation
was not confirmed. However, the significance of patholog-
ical diagnosis or SLB in clinical practice of DM-ILD or CVD-
related ILD has not been determined.23,24 Further, SLB cansometimes induce acute exacerbation in idiopathic
pulmonary fibrosis and other ILD patients.25e27 Fourth, anti-
CADM-140 has been reported exclusively in Japanese
patients thus far.5e7 To establish the clinical relevance of
this antibody, further studies in other ethnic populations
are required.
Despite these limitations, we demonstrated that lower
consolidation/GGA pattern and random GGA patterns as
well as the absence of intralobular reticular opacities were
characteristic of anti-CADM-140-positive DM-ILD. Although
HRCT evaluation can be useful in predicting the presence of
anti-CADM-140 in DM-ILD, further studies are required to
define the prognostic value of HRCT features in anti-CADM-
140-positive DM-ILD.Funding
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